Rituximab
- TRADE NAME: Rituxan (Genentech)
- INDICATIONS: Non-Hodgkin’s lymphoma
- CLASS: Immunosuppressant, Monoclonal antibody
- HALF-LIFE: 60 hours (after first infusion)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Benazepril, Captopril, Clevidipine, Enalapril, Fosinopril, Irbesartan, Lisinopril, Olmesartan, Quinapril, Ramipril
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
RENAL
HEMATOLOGIC
OTIC
LOCAL
OTHER
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of rituximab in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric